SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO, SI, SK, UK)
Ophtaclin vet 10 mg/g eye ointment for dogs, cats and horses (DK, EE, FI, LT, LV, IS, NO, PL, SE)

Ophtocycline eye ointment for dogs, cats and horses (FR)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 gram contains:

Active substances:

Chlortetracycline hydrochloride 10.0 mg (equivalent to 9.3 mg chlortetracycline)

Excipient(s):

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Eye ointment.
Yellowish to yellow homogenous ointment

4. CLINICAL PARTICULARS

4.1 Target species

Dogs, cats and horses.

4.2 Indications for use, specifying the target species

Treatment of keratitis, conjunctivitis and blepharitis caused by *Staphylococcus* spp., *Streptococcus* spp., *Proteus* spp. and/or *Pseudomonas* spp. sensitive to chlortetracycline.

4.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

4.4 Special warnings for each target species

None.

4.5 Special precautions for use

Special precautions for use in animals

Due to the likely variability (time, geographical) in the occurrence of tetracycline resistant bacteria, bacteriological sampling and susceptibility testing are recommended.

Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to chlortetracycline and may decrease the effectiveness of treatment with other tetracyclines due to the potential for cross-resistance.

<u>Special precautions to be taken by the person administering the veterinary medicinal</u> product to animals

Due to possible sensitisation and/or hypersensitivity reactions direct skin contact should be avoided during administration. Wear impermeable gloves when handling the product.

In case of contact with the skin, wash exposed skin with water and soap. If you develop symptoms following exposure such as a skin rash, seek medical advice immediately and show the package leaflet or label to the physician.

4.6 Adverse reactions (frequency and seriousness)

None known.

4.7 Use during pregnancy and lactation

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

No data available.

4.9 Amounts to be administered and administration route

For ocular use only.

Horses: Apply 2-3 cm of ointment (depending on the size of the animal) in the conjunctival sac 4 times a day for 5 days. If after 3 days of treatment no clinical improvement has occurred, alternative therapy should be considered. Dogs and cats: Apply 0.5-2 cm of ointment (depending on the size of the animal) in the conjunctival sac 4 times a day for 5 days. If after 3 days of treatment no clinical improvement has occurred, alternative therapy should be considered.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No data available.

4.11 Withdrawal period(s)

Meat and offal: 1 day

Not authorised for use in horses producing milk intended for human consumption.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: ophthalmologicals: antibiotics

ATCvet code: QS01AA02

5.1 Pharmacodynamic properties

Chlortetracycline hydrochloride is a first-generation tetracycline. It is a predominantly bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome. Chlortetracycline has time-dependent as well as concentration-dependent effects with AUC/MIC being the main PK/PD parameter. Chlortetracycline has a broad spectrum including both aerobic and anaerobic Grampositive and Gram-negative bacteria. Resistance may be mediated by efflux, ribosomal protection and ribosomal modification. Cross-resistance among tetracyclines is common.

5.2 Pharmacokinetic particulars

Chlortetracycline is a non-lipophilic molecule. After topical administration in the eye, systemic absorption is expected to be minimal.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Paraffin, light liquid Wool fat Paraffin, white soft

6.2 Major incompatibilities

Not applicable

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 24 months. Shelf-life after first opening the tube: 14 days

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and composition of immediate packaging

Epoxy resin lacquered aluminium tube with a content of 5 g, with a HDPE cannula and screw cap. One tube in a cardboard box.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V. Wilgenweg 7 3421 TV Oudewater The Netherlands

8. MARKETING AUTHORISATION NUMBER

Vm 41821/4043

9. DATE OF FIRST AUTHORISATION

09 August 2017

10. DATE OF REVISION OF THE TEXT

June 2018

Approved: 12 June 2018

D. Auster